Dose-Dependent Effect of Estrogen Suppresses the Osteo-Adipogenic Transdifferentiation of Osteoblasts via Canonical Wnt Signaling Pathway
Figure 1
Inhibitory effect of 17beta-estradiol on osteogenic markers of osteo-adipogenic transdifferentiation of MC3T3-E1 cells.
After 14 days’ osteogenesis, 17beta-estradiol accompanied with or without ICI was added in adipogenic medium for 14 days and 14 days’ osteogenesis was used as positive control. O14∶14 days’ osteogenesis; O14+O14∶28 days’ osteogenesis; O14+A7∶7 days’ adipogenesis after 14 days’ osteogenesis; O14+A14∶14 days’ adipogenesis after 14 days’ osteogenesis; O14+A14+E2∶14 days’ adipogenesis accompanied with 10−7 M of 17beta-estradiol after 14 days’ osteogenesis; O14+A14+E2+ICI: 14 days’ adipogenesis accompanied with 10−7 M of 17beta-estradiol and ICI after 14 days’ osteogenesis. A: Effect of 17beta-estradiol on the ALP staining of osteo-adipogenic transdifferentiation of MC3T3-E1 cells. B: Effect of 17beta-estradiol on the Alizarin red staining of osteo-adipogenic transdifferentiation of MC3T3-E1 cells. C: Effect of 17beta-estradiol on the ALP activity of osteo-adipogenic transdifferentiation of MC3T3-E1 cells. The control value for ALP activity was 0.418±0.018 unit/mg protein. D: Effect of 17beta-estradiol on the mineralization of osteo-adipogenic transdifferentiation of MC3T3-E1 cells. The control value for mineralization was 0.915±0.020 OD. E: Effect of 17beta-estradiol on the osteogenic mRNA expression of Alp, Col1a1, Runx2 and Ocn. Expression of each target gene was calculated as a relative expression to beta-actin and represented as normalized fold expression. Data are represented as mean±SD of 3 independent experiments. *P<0.05 and **P<0.01.